Coulter Partners places seasoned financial leader David Hastings as CFO at Trevi Therapeutics

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).

David Hastings brings over 25 years of financial leadership in the public life sciences and biopharmaceutical sectors to Trevi. His expertise spans capital raising, commercialization, and investor relations, having secured over $2 billion in equity and debt financing throughout his career. Most recently, Mr. Hastings served as CFO at Arbutus. He previously spent over a decade as CFO and Executive Vice President at Incyte, where he managed the company’s transition from R&D to commercialization following the launch of Jakafi®. During his tenure, he scaled the organization to over 700 employees and co-led major out-licensing deals. Mr. Hastings has also held CFO roles at Unilife and ArQule Inc. and currently chairs the Audit Committee for Scynexis, Inc.

"I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi," said Jennifer Good, President and CEO of Trevi Therapeutics. "His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough.

“Filling this critical role required a search partner that could balance a thorough, robust process with a real sense of urgency, and Coulter Partners delivered on both counts,” added Jennifer Good. “From the very beginning, the Coulter team demonstrated a deep understanding of our specific requirements and the Trevi culture. They worked in close partnership with us, leveraging their extensive network and assessment expertise to provide invaluable insights on prospective candidates. Ultimately, we relied on their trusted advice to identify the right fit for our team, and we are thrilled to welcome a leader of Dave’s caliber to Trevi.”

----

David Hastings, Chief Financial Officer at Trevi Therapeutics, Inc.

Mr. Hastings brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies to Trevi. His accomplishments span capital raising, commercialization, business development, and investor relations management. Throughout his career, Mr. Hastings has raised over $2B in equity and debt financing. Most recently, Mr. Hastings was Chief Financial Officer (CFO) at Arbutus from June 2018 until March 2025. Previously, he was Senior Vice President and CFO of Unilife from 2015 until 2017. Prior to that, he spent the majority of his career as CFO and Executive Vice President at Incyte, a role he held from 2003 to 2014. During his tenure at Incyte, Mr. Hastings oversaw all financial aspects of the company's transition from research and development to commercialization following the launch of Jakafi® (ruxolitinib). He was integral in managing the financial and operational complexities of scaling the company to over 700 individuals. Additionally, he co-led the negotiation of two out-licensing deals for two compounds. Mr. Hastings also previously served as Vice President, CFO and Treasurer at ArQule Inc., where he played an important role in the company's transition into a drug discovery and development organization, and in its two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Currently, Mr. Hastings is a Board member and Chair of the Audit Committee of Scynexis, Inc.

About Trevi Therapeutics, Inc.

About Coulter Partners